Co-Promotion Agreements in MENA: How to Access an Established Sales Force Without Building One From Scratch

For pharmaceutical companies entering a new MENA market, building an independent sales force is simultaneously the most resource-intensive and time-consuming path to commercial presence. In markets where relationships between pharmaceutical sales representatives and healthcare providers are established over years, a defining characteristic of GCC and Maghreb commercial dynamics, the timeline to meaningful sales productivity through a newly built internal team can exceed three to five years. That timeline represents compounding lost revenue in a market growing at 10% annually.

Co-promotion and co-marketing agreements provide an alternative with a fundamentally different risk and resource profile: access to an established commercial infrastructure, an existing healthcare provider network with active relationships, and proven sales execution capability, without the capital commitment of building it independently. The commercial value of this access is real and immediate. The challenge is structuring the agreement to ensure that the access is sustainable, protected, and aligned with the entering company's long-term market positioning objectives.

What a Properly Structured Co-Promotion Agreement Actually Delivers

The commercial value of a co-promotion agreement is directly proportional to the quality of the partner's existing commercial infrastructure in the specific therapeutic area and geographic territory relevant to the entering company's product. General market presence is insufficient: a commercial partner with strong cardiovascular relationships in Saudi Arabia provides a fundamentally different value proposition than one with strong oncology relationships in Morocco. The specificity of the match, between the entering company's product profile and the co-promotion partner's healthcare provider relationships, determines the commercial outcome of the agreement far more than the agreement's financial structure.

Effective co-promotion agreements address five commercial dimensions. First, territory definition: which specific geographic markets does the co-promotion partner cover, and what is the documented depth of their commercial presence in each? Second, promotional commitment: what specific promotional activities does the partner commit to undertaking, with what frequency, and measured against what key performance indicators? Third, revenue sharing: how is revenue allocated between the parties, and how does the allocation adjust as the product's market share grows? Fourth, exclusivity provisions: under what conditions does the co-promotion partner commit to excluding competing products from their promotional focus? Fifth, performance milestones: what commercial targets apply at defined intervals, and what consequences, including agreement modification or termination rights, follow from milestone failure?

The Risks That Most Co-Promotion Agreements Create Through Omission

A co-promotion agreement that does not explicitly protect the entering company's market share in the defined territory creates commercial dependency on a partner whose incentives may eventually diverge. The most common pattern: the co-promotion partner secures a more commercially attractive promotion mandate from a competing product, and their promotional attention shifts accordingly. If the co-promotion agreement lacks explicit exclusivity provisions, performance milestone consequences, and termination rights triggered by promotional underperformance, the entering company has no contractual recourse.

A second omission risk concerns the transition from co-promotion to independent commercial presence. Companies entering MENA markets through co-promotion should, from the outset, structure their agreements to include provisions governing the transition of healthcare provider relationships and market intelligence to the entering company if the partnership terminates. Without these provisions, the co-promotion partner retains the full value of the market access investment, including the HCP relationships that the entering company's product helped build, and the entering company exits the arrangement with no commercial foundation for independent market presence.

The Due Diligence Dimension That Determines Agreement Value

The single most important factor in co-promotion agreement value is the depth and specificity of the partner's commercial infrastructure in the entering company's target therapeutic area and geography. This dimension is also the one most consistently underassessed during partner selection. Standard due diligence processes evaluate financial stability, general market presence, and stated commercial capabilities. The dimension that determines actual co-promotion performance is more granular: how many active HCP relationships does the partner maintain in the specific therapeutic area in the specific target geography? What is the partner's current promotional portfolio, and how does the entering company's product rank in terms of commercial priority relative to the partner's existing commitments?

A distribution partner managing 200 active product registrations across the GCC may be highly capable. They may also be unable to provide the entering company's product with the focused commercial attention the market plan requires. This gap is not visible in standard due diligence. But it becomes measurable, and costly, 18 months after signature, when the commercial trajectory has already been set and modification requires renegotiation from a position of commercial dependency.

Sources: SFDA Commercial Distribution Guidelines; MOHAP Pharmaceutical Marketing Regulations; IQVIA MENA Commercial Infrastructure Analysis 2024; WHO Good Pharmaceutical Distribution Practice Guidelines; GCC Pharmaceutical Affairs Regulations.